Stem Cells Breakethrough – Dramatic Change in Patient With ALS and MG Following BrainStorm’s Therapy

Stem Cells Breakethrough – Dramatic Change in Patient with ALS and MG following BrainStorm’s Therapy – July 3, 2012 Israeli Channel 2 reports: Dramatic Change in Patient with ALS and MG following Compassionate Use of BrainStorm’s Nurown™ Cell Therapy ?NY, Petach Tikva, July 2, 2012. — BrainStorm Cell Therapeutics Inc. (OTC BB: BCLI), Israeli Channel 2 TV interviewed today a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking, balance, posture, muscle strength, appetite, digestion, and weight gain following compassionate treatment with BrainStorm’s NurOwn cell therapy. “Due to the rare disease combination of MG and ALS, this patient was approved for compassionate treatment with BrainStorm’s NurOwn cell therapy” says Professor Dimitrios Karussis of the Neurology Department at The Hadassah Medical Center in Jerusalem, and Principal Investigator of BrainStorm’s current Phase I/II clinical trial. “Within a few weeks following injection with NurOwn cells, the patient showed dramatic improvement in a variety of functions including breathing, speech, walking, muscular strength, and overall well-being. While we cannot draw scientific conclusions based on the outcome of an individual patient, these results are extremely encouraging.” “We are moved by the remarkable results observed following treatment with NurOwn,” said Professor Avi Israeli, BrainStorm’s Chairman of the Board. “We are hopeful that we will continue to see this kind of improvement in all the patients …

Broadway Treatment Center Opens Drug and Alcohol Treatment Facility in CA

Filed under: drug treatment news 2012

ANAHEIM, Calif., Oct. 18, 2012 — ANAHEIM, Calif., Oct. 18, 2012 /PRNewswire/ — Broadway Treatment Center www.broadwaytreatmentcenter.com announces the opening of its alcohol and drug treatment facility in the heart of Orange County California.
Read more on Sacramento Bee

MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now …

Filed under: drug treatment news 2012

"Treatment can help, and patients should talk to their doctors to find out the treatment options available to them." MYRBETRIQ was approved by the U.S. Food and Drug Administration (FDA) on June 28, 2012. The recommended starting dose for MYRBETRIQ …
Read more on Sacramento Bee

PropThink: Pozen Presents Impressive Phase 3 Data At ACG

Filed under: drug treatment news 2012

On October 22, 2012, Pozen (NASDAQ:POZN) presented a full analysis of the integrated results of its two Phase 3 studies comparing PA-325/40 (EC-ASA 325 mg + IR omeprazole 40 mg) to enteric-coated aspirin (EC-ASA) 325 mg in patients requiring aspirin …
Read more on Reuters